REQUEST PRICE

Fields with * are required
Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

MOP (IHC-grade), µ-Opioid Receptor Antibody

Citations
KO-Validated
$ 350.00 *

Prices plus VAT plus shipping costs

Ready to ship today,
Delivery time appr. 5-8 days

Request a quote

Fields with * are required
  • 7TM0319N-IC
  • 100 µl
  • Rabbit
The µ-Opioid Receptor antibody is directed against the distal end of the carboxyl-terminal tail... more

The µ-Opioid Receptor antibody is directed against the distal end of the carboxyl-terminal tail of mouse, rat and human MOP. It detects selectively the canonical form of MOP and none of the putative splice variants. In can be used to detect total MOP receptors in Western blots independent of phosphorylation. The MOP antibody can also be used to isolate and enrich µ-opioid receptors from brain lysates. It also detects MOP in cultured cells and tissue sections by immunohistochemistry. The MOP antibody has been validated using knockout mice (KO-Validated).

  Alternative Names MOP, OPRM1, µ-Opioid Receptor, Mu Receptor IUPHAR... more

 

Alternative Names MOP, OPRM1, µ-Opioid Receptor, Mu Receptor
IUPHAR Target ID  319
UniProt ID  P35372 (human) P42866 (mouse) P33535 (rat)
Western Blot (WB)  1:1000
Immunocytochemistry (ICC) 1:200
Immunohistochemistry (IHC) 1:100
Species Reactivity   Human, Mouse, Rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Immunogen A synthetic peptide with the sequence  LENLEAETAPLP which is present in carboxyl-terminal tail of human, mouse and rat MOP
Form  Liquid
Purification Antigen affinity chromatography
Storage buffer Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide
Storage conditions short-term 4°C, long-term -20°C
Figure 1. Immunohistochemical identification of µ-Opioid Receptor in caudate putamen. Sections... more

Figure 1. Immunohistochemical identification of µ-Opioid Receptor in caudate putamen. Sections were dewaxed, microwaved in citric acid, and incubated with anti-MOP (µ-Opioid Receptor) antibody (7TM0319N-WB) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution.Color was developed by incubation in 3-amino-9-ethylcarbazole (AEC), and sections were counterstained with hematoxylin. Note, MOP receptors were detected at the rim and as islets in the caudate putamen.

Figure 2. Immunohistochemical identification of µ-Opioid Receptor in spinal cord dorsal horn. Sections were dewaxed, microwaved in citric acid, and incubated with anti-MOP (µ-Opioid Receptor) antibody (7TM0319N-WB) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, MOP receptors were uniformly detected at the plasma membrane of lung cells.

Figure 3. Immunohistochemical identification of µ-Opioid Receptor in dorsal root ganglia. Sections were dewaxed, microwaved in citric acid, and incubated with anti-MOP (µ-Opioid Receptor) antibody (7TM0319N-WB) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, MOP receptors were detected predominantly in small- and medium-size cells.

Figure 4. Immunocytochemical identification of µ-Opioid Receptor in HEK293 cells. HEK293 cells stably expressing the complement µ-Opioid Receptor (MOP) were either not exposed or exposed to 10 μM DAMGO ([D-Ala2,N-MePhe4, Gly-ol]-enkephalin) for 30 min and immunocytochemically stained with anti-MOP (µ-Opioid Receptor) antibody (7TM0319N-WB) at a dilution of 1:200. Note, MOP receptors were confined to the plasma membrane in untreated cells (0 min). MOP receptors were seen in perinuclear clusters of vesicles after 30 min DAMGO exposure.

Figure 5. Validation of the µ-Opioid Receptor in transfected HEK293 cells. Native HEK293 cells (MOCK) or HEK293 cells stably expressing the µ-Opioid Receptor (MOP) were lysed and immunoblotted with the phosphorylation-independent anti-MOP antibody (7TM0319N-WB) at a dilution of 1:1000.


Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and... more

Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry. 2014 Nov 15;76(10):767-74. doi: 10.1016/j.biopsych.2014.01.021. Epub 2014 Feb 3. PubMed PMID: 24629717; PubMed Central PMCID: PMC4119866.

Illing S, Mann A, Schulz S. Heterologous regulation of agonist-independent μ-opioid receptor phosphorylation by protein kinase C. Br J Pharmacol. 2014 Mar;171(5):1330-40. doi: 10.1111/bph.12546. PubMed PMID: 24308893; PubMed Central PMCID: PMC3952808.

Just S, Illing S, Trester-Zedlitz M, Lau EK, Kotowski SJ, Miess E, Mann A, Doll C, Trinidad JC, Burlingame AL, von Zastrow M, Schulz S. Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol. 2013 Mar;83(3):633-9. doi: 10.1124/mol.112.082875. Epub 2012 Dec 13. PubMed PMID: 23239825; PubMed Central PMCID: PMC3583494.

Doll C, Pöll F, Peuker K, Loktev A, Glück L, Schulz S. Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol. 2012 Nov;167(6):1259-70. doi: 10.1111/j.1476-5381.2012.02080.x. PubMed PMID: 22725608; PubMed Central PMCID: PMC3504992.

Grecksch G, Just S, Pierstorff C, Imhof AK, Glück L, Doll C, Lupp A, Becker A, Koch T, Stumm R, Höllt V, Schulz S. Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A μ-opioid receptor knock-in mice. J Neurosci. 2011 Sep 28;31(39):13890-6. doi: 10.1523/JNEUROSCI.2304-11.2011. PubMed PMID: 21957251; PubMed Central PMCID: PMC6633166.

Doll C, Konietzko J, Pöll F, Koch T, Höllt V, Schulz S. Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol. 2011 Sep;164(2):298-307. doi: 10.1111/j.1476-5381.2011.01382.x. PubMed PMID: 21449911; PubMed Central PMCID: PMC3174411.

Read, write and discuss reviews... more
Customer evaluation for "MOP (IHC-grade), µ-Opioid Receptor Antibody"
Write an evaluation
Evaluations will be activated after verification.

The fields marked with * are required.

Recently viewed